Canine Keratoconjunctivitis Sicca (KCS): Diagnosis and Treatment

Bottom line

Canine keratoconjunctivitis sicca (KCS) is diagnosed with the Schirmer tear test-1 (STT-1) and treated first-line with a topical calcineurin inhibitor — ciclosporin or tacrolimus — layered over tear replacement. Most immune-mediated cases respond, but ciclosporin non-responders are switched to (or combined with) tacrolimus, neurogenic KCS is driven by oral or topical pilocarpine rather than immunomodulators, and refractory quantitative deficits are candidates for parotid duct transposition. Injectable platelet-rich plasma (PRP) with oral omega-3 is an emerging adjunct for tear-film stability and surface inflammation — not a replacement for calcineurin inhibitors.

Condition facts

Definition. KCS is deficiency of the aqueous component of the precorneal tear film, usually quantitative (reduced lacrimal and third-eyelid gland secretion) and frequently accompanied by a qualitative tear-film defect. [4]

Signalment and etiology. The dominant cause is immune-mediated destruction of the lacrimal and nictitans glands, over-represented in breeds such as the West Highland White Terrier, Cocker Spaniel, English Bulldog, Lhasa Apso, Shih Tzu, and Cavalier King Charles Spaniel, and in brachycephalics generally. [4] Other etiologies include neurogenic KCS (facial-nerve/parasympathetic denervation of the lacrimal gland, classically with ipsilateral xeromycteria — a dry, crusted nostril), iatrogenic causes (sulfonamides, etodolac, gland-of-the-third-eyelid excision), endocrine disease, congenital gland aplasia, and infection (e.g., canine distemper). [5]

Clinical signs. Mucoid to mucopurulent discharge, conjunctival hyperemia, blepharospasm, corneal changes (neovascularization, pigmentation, keratitis), and recurrent or non-healing corneal ulceration. Lackluster, "dry-looking" corneas and tenacious discharge that returns hours after cleaning are hallmark. [4]

How to diagnose it

Diagnosis rests on the STT-1 (no topical anesthetic) read at one minute, interpreted against corneal and conjunctival signs. Using the standard canine framework: >15 mm/min is normal, 10–15 mm/min is marginal/early, 5–10 mm/min is moderate, and <5 mm/min is severe. [4] A dog with compatible ocular-surface disease and STT-1 below 15 mm/min supports KCS; values below 10 mm/min with clinical signs are diagnostic. Always test before instilling anything that alters tear volume, and interpret STT-1 in light of breed — brachycephalic globes and eyelid conformation can shift readings. [4]

Complete the workup with fluorescein staining (ulceration risk is high in KCS), tear break-up time (TBUT) when a qualitative defect is suspected, and a targeted search for neurogenic disease: check for ipsilateral xeromycteria, unilateral presentation, and cranial-nerve deficits, because neurogenic KCS will not respond to immunomodulators and demands a different drug class. [5]

First-line treatment: calcineurin inhibitors plus tear replacement

For immune-mediated KCS, a topical calcineurin inhibitor is first-line and is started at the time of diagnosis. [4]

Ciclosporin. Topical ciclosporin (0.2% ointment, or compounded 1–2% solutions) is the FDA-approved mainstay. Start twice daily; once tear production and clinical signs stabilize — typically over the first one to two months — many patients can be reduced to once daily. [4] Clinical improvement does not always track a rise in STT-1, and treatment is generally lifelong; premature discontinuation reliably relapses. As of 2015 review-level data, roughly 20–30% of dogs are considered inadequate ciclosporin responders. [4]

Tacrolimus. Topical tacrolimus (commonly compounded 0.02–0.03% aqueous suspension, twice daily) shares ciclosporin's calcineurin-inhibiting mechanism but is more potent on a concentration basis and is the standard step for ciclosporin non-responders; it can also be used in combination. [4] A 2023 randomized 6-month trial found 0.03% tacrolimus normalized STT-1 within roughly one month and outperformed injectable PRP on the core aqueous-production and goblet-cell endpoints, reinforcing calcineurin inhibitors as the reference standard. [2]

Tear replacement. Artificial tears and lubricants are adjunctive in every case and are the immediate first agents for comfort while immunomodulators take effect. Frequency scales with severity — six or more times daily in milder disease, up to hourly in severe deficits — and higher-viscosity or hyaluronate/carmellose formulations extend residence time. [4] Topical antibiotics and short-course anti-inflammatories are added for secondary bacterial infection and keratitis as needed.

Neurogenic KCS: pilocarpine, not calcineurin inhibitors

Neurogenic KCS results from loss of parasympathetic drive to the lacrimal gland, so immunomodulators do not address the lesion. The mainstays are cholinergic (parasympathomimetic) stimulation with pilocarpine plus lubrication. [5] Oral pilocarpine (typically a 1–2% solution dosed on food and titrated to effect) has the advantage of also resolving the ipsilateral xeromycteria; topical pilocarpine is an alternative. In a case series of 34 dogs with neurogenic KCS, pilocarpine (systemic and/or topical) with or without a lacrimostimulant improved clinical signs, raised STT-1, and resolved xeromycteria in a meaningful proportion of treated dogs. [5] Titrate carefully and watch for cholinergic toxicity (hypersalivation, vomiting, diarrhea, bradycardia); a subset does not respond, and some neurogenic cases resolve spontaneously.

Refractory quantitative KCS: parotid duct transposition

When a severe aqueous deficit fails medical management — persistently low STT-1 despite maximal calcineurin-inhibitor and lubricant therapy, or an owner unable to sustain lifelong topical dosing — parotid duct transposition (PDT) reroutes the parotid salivary duct to the conjunctival sac so saliva wets the ocular surface. In a retrospective review of 92 eyes (56 dogs) with a mean follow-up of ~39 months, the surgical success rate was 92%, with total failure in 8% (chiefly severe saliva intolerance). [6] PDT is definitive for the aqueous deficit but not benign: complications occur in roughly half of eyes, including periocular and corneal mineral precipitates (saliva is mineral-rich), moist dermatitis, blepharitis, and duct stenosis. Manage precipitates with topical EDTA chelation and ongoing surface care; some eyes still require topical medication after surgery. [6] PDT does not correct a qualitative tear-film defect and is reserved for genuinely refractory quantitative disease.

Adjuncts: injectable PRP and oral omega-3

Injectable homologous PRP and oral omega-3 fatty acids act on different arms of the tear film — PRP delivers concentrated growth factors toward the aqueous/gland compartment, while omega-3 targets lipid-layer stability — and are best framed as adjuncts, not first-line therapy. [1][3]

In a 6-month randomized trial of 22 dogs (44 eyes) with bilateral KCS, subconjunctival homologous PRP alone and PRP plus oral omega-3 both significantly raised STT-1 from baseline with no difference between arms, so omega-3 added nothing to aqueous production. [1] The combination's distinguishing benefit was tear-film quality: TBUT was significantly higher with added omega-3 from month 3 through month 6, alongside faster corneal-ulcer resolution, greater goblet-cell recovery, and larger reductions in lacrimal-gland lymphocytes and neutrophils on cytology and histopathology. [1] That STT-versus-TBUT dissociation mirrors human data — a double-blind RCT of oral omega-3 (EPA 325 mg / DHA 175 mg twice daily) improved TBUT (mean gain 2.54 s vs 0.13 s for placebo) far more than Schirmer output, giving the canine finding a coherent lipid-layer rationale. [3]

Practically: for a patient already on a calcineurin inhibitor with persistent surface instability, epithelial disease, or breakthrough ulceration, an oral omega-3 adjunct is low-risk and mechanistically defensible, and injectable PRP is a reasonable in-clinic adjunct where available. [1][3] Temper expectations against the evidence base — the anchor trial is a single-center, brachycephalic-heavy study of 22 dogs, unblinded to intervention type, with no follow-up past 6 months. [1] As of 2025, nothing here displaces ciclosporin or tacrolimus as first-line. PRP was well tolerated, with transient eyelid edema in ~4.5% of dogs resolving within minutes. [1]

Monitoring and prognosis

Recheck STT-1, fluorescein staining, and TBUT at intervals appropriate to severity — early re-evaluation within the first month to confirm response, then periodically for life. [4] Counsel owners that immune-mediated KCS is a lifelong, medically managed disease: adherence to daily therapy is the single largest determinant of outcome, and stopping calcineurin inhibitors reliably relapses. With early diagnosis and consistent treatment the prognosis for comfort and vision is good; delayed or under-treated disease progresses to corneal pigmentation, scarring, and vision loss. [4]

Frequently Asked Questions

What Schirmer tear test value confirms KCS in a dog?

STT-1 above 15 mm/min is normal; 10-15 mm/min is marginal/early, 5-10 mm/min moderate, and below 5 mm/min severe. A dog with compatible ocular-surface disease and STT-1 under 15 mm/min supports KCS, and values under 10 mm/min with clinical signs are diagnostic. Always read STT-1 before instilling anything that alters tear volume. [4]

Is ciclosporin or tacrolimus first-line for canine dry eye?

Ciclosporin (0.2% ointment or compounded 1-2% solution, starting twice daily) is the FDA-approved first-line calcineurin inhibitor for immune-mediated KCS. Tacrolimus is more potent per concentration and is the standard step for the roughly 20-30% of dogs that respond inadequately to ciclosporin, and may be used in combination. [4]

How do I treat neurogenic KCS differently?

Neurogenic KCS does not respond to ciclosporin or tacrolimus because the lesion is loss of parasympathetic drive, not immune-mediated gland destruction. Treat with cholinergic stimulation — oral or topical pilocarpine, titrated to effect — plus lubrication; oral pilocarpine also resolves the ipsilateral xeromycteria. Watch for cholinergic toxicity. [5]

When should a KCS dog be referred for parotid duct transposition?

Consider PDT for severe quantitative KCS that fails maximal medical therapy, or when an owner cannot sustain lifelong topical dosing. A retrospective of 92 eyes reported a 92% surgical success rate, but complications occurred in about half of eyes (mineral precipitates, moist dermatitis, blepharitis). PDT does not correct a qualitative tear-film defect. [6]

Does injectable PRP or oral omega-3 work for canine KCS?

Both are adjuncts. In a randomized trial, PRP raised STT-1, and adding oral omega-3 significantly improved TBUT, corneal-ulcer resolution, and goblet-cell recovery from month 3 to 6 — but omega-3 added nothing to aqueous production. Read PRP plus omega-3 as an adjunct for tear-film stability and surface inflammation, not a replacement for calcineurin inhibitors. [1][3]

How long until ciclosporin improves a dog's tear production?

Clinical and tear-production improvement typically appears over the first one to two months of twice-daily topical ciclosporin, after which many dogs can be tapered to once daily. Treatment is lifelong; discontinuation reliably relapses, and improvement in comfort can precede or exceed measured STT-1 gains. [4]

How often should artificial tears be used in KCS?

Frequency scales with severity — six or more times daily in milder disease and up to hourly in severe aqueous deficits — as immediate comfort therapy alongside immunomodulators. Higher-viscosity or hyaluronate/carmellose formulations extend residence time and reduce dosing burden. [4]

Is canine KCS curable?

Immune-mediated KCS is managed, not cured. With early diagnosis and consistent daily therapy the prognosis for comfort and vision is good; adherence is the largest determinant of outcome. Untreated or under-treated disease progresses to corneal pigmentation, scarring, and vision loss. [4]